301333 Stock Overview
Provides clinical research outsourcing services for pharmaceutical and medical device companies, and scientific research institutions in China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
R&G PharmaStudies Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥40.12 |
| 52 Week High | CN¥81.38 |
| 52 Week Low | CN¥33.05 |
| Beta | 0.41 |
| 11 Month Change | 2.53% |
| 3 Month Change | 17.04% |
| 1 Year Change | -44.69% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.68% |
Recent News & Updates
R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20
Jul 01
Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?
Jun 06Shareholder Returns
| 301333 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 3.1% | 4.6% | 5.4% |
| 1Y | -44.7% | -40.6% | -16.2% |
Return vs Industry: 301333 underperformed the CN Life Sciences industry which returned -40.6% over the past year.
Return vs Market: 301333 underperformed the CN Market which returned -16.2% over the past year.
Price Volatility
| 301333 volatility | |
|---|---|
| 301333 Average Weekly Movement | 8.3% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.4% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 301333 has not had significant price volatility in the past 3 months.
Volatility Over Time: 301333's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 2,042 | David Wu | www.rg-pharma.com |
R&G PharmaStudies Co., Ltd. provides clinical research outsourcing services for pharmaceutical and medical device companies, and scientific research institutions in China. It offers clinical trial consulting, clinical trial operation, data management and statistical analysis, technical services and solutions, biostatistical quantitative scientific support, and various services related to the clinical trial data monitoring committee, including participating in the committee or relevant statistical analysis for the committee. The company also provides clinical pharmacology services; biological sample testing services to analyze and detect the biological samples collected during the clinical trial, and to determine the concentration of the original drug and/or metabolites; and clinical trial site management services.
R&G PharmaStudies Co., Ltd. Fundamentals Summary
| 301333 fundamental statistics | |
|---|---|
| Market cap | CN¥3.80b |
| Earnings (TTM) | CN¥135.07m |
| Revenue (TTM) | CN¥738.42m |
28.5x
P/E Ratio5.2x
P/S RatioIs 301333 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301333 income statement (TTM) | |
|---|---|
| Revenue | CN¥738.42m |
| Cost of Revenue | CN¥443.81m |
| Gross Profit | CN¥294.61m |
| Other Expenses | CN¥159.54m |
| Earnings | CN¥135.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.41 |
| Gross Margin | 39.90% |
| Net Profit Margin | 18.29% |
| Debt/Equity Ratio | 0% |
How did 301333 perform over the long term?
See historical performance and comparison